Abstract

BackgroundAccumulating evidence shows that N6-methyladenine (m6A) modulators contribute to the etiology and progression of colorectal cancer (CRC). However, the exact mechanisms of m6A reader involved in glycolytic metabolism remain vague. This article aimed to crosstalk the m6A reader with glycolytic metabolism and reveal a new mechanism for the progression of CRC.MethodsThe relationship between candidate lncRNA and m6A reader was analyzed by bioinformatics, ISH and IHC assays. In vivo and in vitro studies (including MTT, CFA, trans-well, apoptosis, western blot, qRT-PCR and xenograft mouse models) were utilized to explore the biological functions of these indicators. Lactate detection, ATP activity detection and ECAR assays were used to verify the biological function of the downstream target. The bioinformatics, RNA stability, RIP experiments and RNA pull-down assays were used to explore the potential molecular mechanisms.ResultsWe identified that the crosstalk of the m6A reader IMP2 with long-noncoding RNA (lncRNA) ZFAS1 in an m6A modulation-dependent manner, subsequently augmented the recruitment of Obg-like ATPase 1 (OLA1) and adenosine triphosphate (ATP) hydrolysis and glycolysis during CRC proliferation and progression. Specifically, IMP2 and ZFAS1 are significantly overexpressed with elevated m6A levels in CRC cells and paired CRC cohorts (n = 144). These indicators could be independent biomarkers for CRC prognostic prediction. Notably, IMP2 regulated ZFAS1 expression and enhanced CRC cell proliferation, colony formation, and apoptosis inhibition; thus, it was oncogenic. Mechanistically, ZFAS1 is modified at adenosine +843 within the RGGAC/RRACH element in an m6A-dependent manner. Thus, direct interaction between the KH3–4 domain of IMP2 and ZFAS1 where IMP2 serves as a reader for m6A-modified ZFAS1 and promotes the RNA stability of ZFAS1 is critical for CRC development. More importantly, stabilized ZFAS1 recognizes the OBG-type functional domain of OLA1, which facilitated the exposure of ATP-binding sites (NVGKST, 32–37), enhanced its protein activity, and ultimately accelerated ATP hydrolysis and the Warburg effect.ConclusionsOur findings reveal a new cancer-promoting mechanism, that is, the critical modulation network underlying m6A readers stabilizes lncRNAs, and they jointly promote mitochondrial energy metabolism in the pathogenesis of CRC.

Highlights

  • Accumulating evidence shows that N6-methyladenine ­(m6A) modulators contribute to the etiology and progression of colorectal cancer (CRC)

  • Qing et al revealed that R-2-hydroxyglutarate attenuated aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis [5]; Liu et al demonstrated that tumors could exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance [6]; Wang et al indicated that LncRNA LINRIS promoted aerobic glycolysis by stabilizing IGF2BP2 in CRC [7]

  • Ectopic IMP2 enhances, whereas knockdown IMP2 suppresses, the stability and expression (See figure on page.) Fig. 8 IMP2 stabilized ZNFX1 antisense ribonucleic acid (RNA) 1 (ZFAS1) promotes the progression of CRC by promoting the ATPase activity of Obg-like ATPase 1 (OLA1)

Read more

Summary

Introduction

Accumulating evidence shows that N6-methyladenine ­(m6A) modulators contribute to the etiology and progression of colorectal cancer (CRC). This article aimed to crosstalk the ­m6A reader with glycolytic metabolism and reveal a new mechanism for the progression of CRC. Reversible ­m6A modification of RNA plays critical roles in various aspects of the fate of RNA metabolism during tumor occurrence and progression, such as in pre-mRNA splicing, translocation, mRNA stability or decay, and lncRNA processing [2, 3]. Qing et al revealed that R-2-hydroxyglutarate attenuated aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis [5]; Liu et al demonstrated that tumors could exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance [6]; Wang et al indicated that LncRNA LINRIS promoted aerobic glycolysis by stabilizing IGF2BP2 in CRC [7]. Targeting interactions mediated by ­m6A epigenetic modification to metabolic glycolysis may contribute to providing better individual therapeutic interventions and may help in providing precise treatment for patients with CRC

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.